Progression‐free survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower progression‐free survival: all participants compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Progression‐free survival in people with central nervous system disease · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower progression‐free survival in people with central nervous system… compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Overall adverse events · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor showed no clear difference in overall adverse events compared with any cytotoxic chemotherapy (low certainty).
1 finding from 1 review
Grade 5 adverse events (excluding progressive disease) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with any cytotoxic chemotherapy (low certainty).
1 finding from 1 review
Overall survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower overall survival compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Overall response rate · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor probably leads to higher overall response rate compared with any cytotoxic chemotherapy (moderate certainty).
1 finding from 1 review
Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower health‐related quality of life: time to deterioration in composite… compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Intervention not reported
Antibiotics prior to long‐term CVC insertion versus control: catheter‐related infections · adults and children diagnosed with an oncologic disease with a newly‐inserted long‐term CVC who were at risk of neutropenia due to…
The intervention showed no clear difference in antibiotics prior to long‐term CVC insertion versus control:… (moderate certainty).
1 finding from 1 review
Intervention not reported
Antibiotic versus heparin only lock/flush solution: catheter‐related infections · adults and children diagnosed with an oncologic disease with a newly‐inserted long‐term CVC who were at risk of neutropenia due to…
The intervention probably leads to lower antibiotic versus heparin only lock/flush solution: catheter‐related… (moderate certainty).
1 finding from 1 review
Intervention not reported
Antibiotic versus heparin only lock/flush solution: adverse events · adults and children diagnosed with an oncologic disease with a newly‐inserted long‐term CVC who were at risk of neutropenia due to…
1 finding from 1 review
Overall survival · EGFR M+ patients with NSCLC
Afatinib showed no clear difference in overall survival compared with chemotherapy (high certainty).
1 finding from 1 review
Progression‐free survival · EGFR M+ patients with NSCLC
Afatinib leads to lower progression‐free survival compared with chemotherapy (high certainty).
1 finding from 1 review
Overall survival: Median length of · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in overall survival (OS)median compared with chemotherapy regimens without capecitabine (high certainty).
1 finding from 1 review
Disease-free survival · patients with early breast cancer
Capecitabine‐containing regimens showed no clear difference in disease‐free survival (DFS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
DFS: hormone receptor‐positivemedian · patients with early breast cancer
Capecitabine‐containing regimens showed no clear difference in DFS: hormone receptor‐positivemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
DFS: hormone receptor‐negativemedian · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower DFS: hormone receptor‐negativemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
OS: hormone receptor‐positivemedian · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (high certainty).
1 finding from 1 review
Overall survival: Median length of · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Febrile neutropenia · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Diarrhoea · patients with early breast cancer
Capecitabine‐containing regimens probably leads to higher diarrhoea compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review